← All Sponsors
SPONSOR

Immatics Biotechnologies GmbH

Total Trials
1
Recruiting
1
Phases
Phase 1
Conditions studied: Refractory CancerRecurrent CancerSolid Tumor, AdultCancer
NCT05359445 Phase 1
Recruiting

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Refractory Cancer
Germany View Trial →